FINANCE:Celgene Taps Abide Therapeutics for Enzyme Targeting Technology
Biotech will get $50 million, backers have potential exit.
Abide Therapeutics entered into a strategic collaboration with Celgene to discover and develop new drugs in inflammation and immunology. The partners will use Abide’s technology to selectively target serine hydrolases, one of the largest enzyme families involved in regulating human physiology. Read More